Hans Marcus Bosson
Chief Executive Officer at QUIAPEG PHARMACEUTICALS HOLDING AB
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Per Thoresen | M | 71 | 3 years | |
Marek Kwiatkowski | M | 74 | 7 years | |
Vidar Wendel-Hansen | M | 65 |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | 6 years |
Lars Gerhard Linzander | M | 70 | 15 years | |
Hjördis Berg | M | - | 2 years | |
Supaporn Sawadjoon | M | 46 | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Steen Kroyer | M | - | 4 years | |
Jan Anders Vedin | M | 82 |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | 10 years |
Hans Johan Albert von Kantzow | M | 53 | 15 years | |
Stig Lökke Pedersen | M | 62 | 2 years | |
Mats Bo Johan Nilsson Bernitz | M | 54 | - | |
Cecilia Kemi | M | 48 | - | |
Leif Niclas Fredrik Löwgren | M | 54 | - | |
Helena Lindberg | F | - |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | 4 years |
Bengt Sparf | M | - |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | 10 years |
Stefan Persson | M | - |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | 9 years |
Sture Jan-Gunnar Gustafsson | M | 74 |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | - |
Erik Magnusson | M | 63 | 1 years | |
Jonas Sven Peter Jarvius | M | 53 | - | |
Deborah Harland | M | 64 |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | - |
Kent Alan Gossett | M | - |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | 4 years |
Claes Lundberg | M | 73 |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | 6 years |
Erik Petter Wingstrand | M | 59 |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | 7 years |
Sven-Erik Dahlén | M | - |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | 5 years |
Jonas Karl Olaf Brambeck | M | 66 |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | 10 years |
Jens W. Kindtler | M | - |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | 7 years |
Johan Rutger Christenson | M | 65 |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | 5 years |
Jonas Frick | M | 66 |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | - |
Staffan Lindstrand | M | 62 |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | - |
Nils Owe Engström | M | - | - | |
Kajsa Grafström | M | - | 1 years |
Statistics
Country | Connections | % of total |
---|---|---|
Sweden | 31 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Hans Marcus Bosson
- Personal Network